IOVANCE Biotherapeutics: chief medical officer Noah Berkowitz received 450,000 shares

What happened

• Noah Berkowitz, chief medical officer, received three awards totaling 450,000 shares (135,000; 180,000; 135,000) on Sep 30, 2026. Each award was reported as acquired at $0.00, total value $0.00. The filing describes these as derivative awards (restricted stock units and performance stock units per the footnotes).

Key details

• Transaction date and price: Sep 30, 2026, acquired at $0.00 per share.
• Shares owned after the transaction: not reported in the Form 4.
• Relevant footnotes from the filing:
  • F1: Vesting schedule — one-third vest on the one-year anniversary of the grant; the remainder vests in eight equal quarterly installments over the next two years, subject to continued employment.
  • F2: Each RSU represents a contingent right to receive one share of common stock.
  • F3: Each PSU converts into one share of common stock.
  • F4: Up to 135,000 shares underlying the PSUs may be earned subject to achievement of certain regulatory milestones.
  • F5: Earned PSUs vest on the date the issuer publicly discloses receipt of the regulatory milestones on a Form 8-K.
• Filing date and period of report: filed Oct 2, 2026, period of report Sep 30, 2026. The Form 4 does not indicate a late filing flag.

Why it may matter

• These were awards/grants of derivative securities (RSUs and PSUs), not open-market purchases or sales.
• PSUs are contingent on regulatory milestones (up to 135,000 shares) and vest upon public disclosure on a Form 8-K; RSUs follow the time-based vesting schedule in F1.
• A filing does not show why the insider traded or why the company acted.